Echo Therapeutics Announces First Quarter 2012 Financial Results
PHILADELPHIA, May 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the quarter ended March 31, 2012.  Echo's Quarterly Report on Form 10-Q as filed with the SEC is available through Echo's website at . Recent Corporate Highlights Echo initiated clinical studies of its Symphony tCGM System in critically ill patients in two hospitals.  The company announced positive results from its clinical study conducted at Tufts Medical Center in Boston, Massachusetts.  Data from tha ...

Cash Store Financial Releases Second Quarter Results
EDMONTON, May 10, 2012 /PRNewswire/ - The Cash Store Financial Services Inc. (Cash Store Financial) (TSX: CSF; NYSE: CSFS) today announced results for its second quarter ended March 31, 2012. The following financial results are expressed in Canadian dollars. On January 31, 2012, the Company completed a 5 year Senior Secured Note of $C132.5 million, the proceeds of which were used to purchase loans receivable and other intangible assets from third-party lenders. Various adjustments for the quarter relate to this transaction. Highlights for the three months ended March 31, 2012 (a table of results can be found at the end of this news release): Adjusted net cash income for the second quarter ended March 31, 2012, ...

YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
MISSISSAUGA, ON, May 11, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology and cancer related products, today reported operational and financial results for its third quarter of fiscal 2012, ended March 31, 2011. "In the past few months we delivered robust Phase I/II results for our JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis and we raised an additional $80 million principally to support the further advancement of this drug," said Dr.

Sutor Technology Group Limited Announces Third Quarter of Fiscal Year 2012 Financial Results
CHANGSHU, China, May 11, 2012 /PRNewswire-Asia-FirstCall/ -- Sutor Technology Group Limited (the "Company" or "Sutor") (Nasdaq: SUTR), a leading China-based non-state-owned manufacturer and distributor of high-end fine finished steel products and welded steel pipes used by a variety of downstream applications, today announced its unaudited financial results for the third quarter of fiscal year 2012 ended March 31, 2012. Third Quarter 2012 Highlights: 3QFY2012 3Q FY2011 Change Revenues (million) $ 109.9 $ 101.4 8.4% Gross profit (million) $ 7.9 $ 8.6 -8.1% Gross margin           7.2% 8.5% -15.3% Net income (million) $ 1.2 $3.5 -65. ...